Contact
searchSearch
HMP Global

Multiple Sclerosis Topic Center

Featured Article

News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
News
Transcriptional Signatures of Multiple Sclerosis May Explain Female-Biased Gene Expression
10/29/2024
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the...
10/29/2024
First Report Managed Care
News
Data on Black/African American and Hispanic/Latino Patients With Relapsing Multiple Sclerosis Receiving Ocrelizumab: CHIMES Trial 
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
Risk of Disease Activity After Discontinuation of Disease-Modifying Drugs for Multiple Sclerosis
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care
News
Subcutaneous Ocrelizumab Shows Noninferiority to Intravenous Administration in Multiple Sclerosis Treatment
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care
News
COVID-19 Vaccination Does Not Increase Relapse Risk in Patients With Multiple Sclerosis
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
The Role of BDNF in MS Remains Ambiguous
08/16/2024
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the...
08/16/2024
First Report Managed Care
News
‘Hidden’ Signs May Signal Subclinical Progression in Early MS
07/15/2024
Focusing solely on relapse rates and magnetic resonance imaging (MRI) lesion activity to track disease progression in patients with early multiple sclerosis (MS) may miss indicators of subclinical disease activity, with important implications...
Focusing solely on relapse rates and magnetic resonance imaging (MRI) lesion activity to track disease progression in patients with early multiple sclerosis (MS) may miss indicators of subclinical disease activity, with important implications...
Focusing solely on relapse rates...
07/15/2024
First Report Managed Care
News
MS Disease-Modifying Treatments Affect Cellular Response to Epstein-Barr Virus Antigen
06/14/2024
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to...
06/14/2024
First Report Managed Care
News
Patient Diagnosed With Clinically Isolated Syndrome After Traumatic Brain Injury: Case Study
05/30/2024
Researchers presented a case study of a 71-year-old White man who was diagnosed with clinically isolated syndrome (CIS) after experiencing a traumatic brain injury.
Researchers presented a case study of a 71-year-old White man who was diagnosed with clinically isolated syndrome (CIS) after experiencing a traumatic brain injury.
Researchers presented a case...
05/30/2024
First Report Managed Care

Newsfeed

News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
News
Transcriptional Signatures of Multiple Sclerosis May Explain Female-Biased Gene Expression
10/29/2024
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the American Academy of Neurology 2024 Annual Meeting identified distinct transcriptional signatures in multiple sclerosis (MS) that may explain its higher prevalence in females.
A study presented at the...
10/29/2024
First Report Managed Care
News
Data on Black/African American and Hispanic/Latino Patients With Relapsing Multiple Sclerosis Receiving Ocrelizumab: CHIMES Trial 
10/28/2024
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing multiple sclerosis (MS).
The CHIMES study assessed the...
10/28/2024
First Report Managed Care
News
Risk of Disease Activity After Discontinuation of Disease-Modifying Drugs for Multiple Sclerosis
10/25/2024
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of disease activity in patients with multiple sclerosis after discontinuing disease-modifying drugs.
Researchers examined the risk of...
10/25/2024
First Report Managed Care
News
Subcutaneous Ocrelizumab Shows Noninferiority to Intravenous Administration in Multiple Sclerosis Treatment
10/25/2024
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study demonstrates that subcutaneous ocrelizumab is noninferior to intravenous administration in efficacy and safety for treating relapsing and primary progressive multiple sclerosis.
The OCARINA II study...
10/25/2024
First Report Managed Care
News
COVID-19 Vaccination Does Not Increase Relapse Risk in Patients With Multiple Sclerosis
09/19/2024
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not increase the risk of severe relapse for most patients with multiple sclerosis (MS), according to study results published in the American Journal of Neurology.
COVID-19 vaccination does not...
09/19/2024
First Report Managed Care
News
The Role of BDNF in MS Remains Ambiguous
08/16/2024
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the role of brain-derived neurotrophic factor (BDNF) in patients with multiple sclerosis (MS) is largely inconclusive, according to a review article published in Frontiers in Neurology.
Current evidence regarding the...
08/16/2024
First Report Managed Care
News
‘Hidden’ Signs May Signal Subclinical Progression in Early MS
07/15/2024
Focusing solely on relapse rates and magnetic resonance imaging (MRI) lesion activity to track disease progression in patients with early multiple sclerosis (MS) may miss indicators of subclinical disease activity, with important implications...
Focusing solely on relapse rates and magnetic resonance imaging (MRI) lesion activity to track disease progression in patients with early multiple sclerosis (MS) may miss indicators of subclinical disease activity, with important implications...
Focusing solely on relapse rates...
07/15/2024
First Report Managed Care
News
MS Disease-Modifying Treatments Affect Cellular Response to Epstein-Barr Virus Antigen
06/14/2024
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to Epstein-Barr virus nuclear antigen-1 (EBNA-1) may benefit patients with multiple sclerosis (MS), suggests a study published in the journal Neurology: Neuroimmunology & Neuroinflammation.
Testing cellular response to...
06/14/2024
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use